NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Shareholders of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its Board of Directors has authorized a share repurchase plan on Saturday, December 2nd 2017, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Tuesday, May, 1st. The company reported $1.05 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.05. The company had revenue of $10.04 billion for the quarter, compared to analysts' expectations of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. The company's revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.88 earnings per share. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 brokers have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $58.83 to $72.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $66.0519 in the next year. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Ratings for Merck & Co., Inc..

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Merck & Co., Inc. saw a decrease in short interest in June. As of June 29th, there was short interest totalling 17,153,866 shares, a decrease of 21.6% from the June 15th total of 21,867,505 shares. Based on an average daily trading volume, of 11,109,077 shares, the short-interest ratio is currently 1.5 days. Currently, 0.6% of the shares of the company are short sold. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News headlines about MRK stock have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merck & Co., Inc. earned a news sentiment score of 0.19 on Accern's scale. They also gave news stories about the company an impact score of 44.70 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Merck & Co., Inc.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), Bank of Montreal Can (0.14%), NN Investment Partners Holdings N.V. (0.08%), Retirement Systems of Alabama (0.08%) and Manning & Napier Group LLC (0.07%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Hartford Investment Management Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Stralem & Co. Inc., Manning & Napier Group LLC, Nippon Life Global Investors Americas Inc., Radnor Capital Management LLC and Highland Capital Management LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, Nisa Investment Advisors LLC, LGT Capital Partners LTD., Retirement Systems of Alabama, Calamos Advisors LLC, DnB Asset Management AS and Welch & Forbes LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $62.51.

Merck & Co., Inc. has a market capitalization of $168.59 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]